申请人:St. Jude Children's Research Hospital
公开号:US10647702B2
公开(公告)日:2020-05-12
The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
本发明的化合物是 MDM2 和 MDMX 的拮抗剂,对 MDM2 和 MDMX 的特异性优于其他蛋白,对 MDMX 的结合亲和力优于 MDM2。因此,这些化合物可以调节 p53 的活性,治疗各种癌症。本摘要旨在作为在特定技术领域进行搜索的扫描工具,并非对本发明的限制。